PD-L1 expression was also associated with downregulation of microRNAs previously shown to have tumour suppressor activity…
Raleigh, NC (PRWEB)
June 25, 2017
Australian researchers studying the protein PD-L1 have developed a way to potentially turn off the mechanism that lets mesothelioma tumors hide from the immune system. Surviving Mesothelioma has the full story. Click here to read it now.
Doctors at the Asbestos DIseases Research Institute at the University of Sydney found key differences in the action of certain microRNAs among mesothelioma patients with elevated levels of PD-L1.
“In the same patient series, PD-L1 expression was also associated with downregulation of microRNAs previously shown to have tumour suppressor activity in malignant pleural mesothelioma,” writes Steven C. Kao, the lead author on the paper.
According to the study in the Journal of Thoracic Oncology, the researchers determined that it is possible to downregulate PD-L1 expression by inserting “mimic” microRNAs into mesothelioma cells in the lab.
“This is especially noteworthy since mesothelioma patients who test positive for PD-L1 overexpression are more likely to have a non-epithelioid type of mesothelioma and poorer odds of survival,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.
For the details of the new clinical trial and more about PD-L1 and microRNAs in mesothelioma, see MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma, now available on the Surviving Mesothelioma website.